Page last updated: 2024-10-30
lansoprazole and Diabetes Mellitus, Type 1
lansoprazole has been researched along with Diabetes Mellitus, Type 1 in 3 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Children aged 6-12 years with type 1 diabetes were allocated to receive cholecalciferol and lansoprazole (Group 1) or no treatment (Group 2)." | 1.72 | Combination therapy with lansoprazole and cholecalciferol is associated with a slower decline in residual beta-cell function and lower insulin requirements in children with recent onset type 1 diabetes: results of a pilot study. ( Attri, SV; Dayal, D; Gupta, VK; Reddy, R; Sachdeva, N, 2022) |
Research
Studies (3)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
Authors
| Authors | Studies |
|---|
| Reddy, R | 3 |
| Dayal, D | 3 |
| Sachdeva, N | 3 |
| Attri, SV | 3 |
| Gupta, VK | 3 |
| Levetan, C | 1 |
| Pozzilli, P | 1 |
| Jovanovic, L | 1 |
| Schatz, D | 1 |
| Griffin, KJ | 1 |
| Thompson, PA | 1 |
| Gottschalk, M | 1 |
| Kyllo, JH | 1 |
| Rabinovitch, A | 1 |
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A Phase IIB/III Multicenter Randomized Trial to Evaluate the Combination of Low-Dose Cyclosporine and Omeprazole Versus Omeprazole Alone in Participants With New Onset Type 1 Diabetes.[NCT01762644] | Phase 3 | 0 participants (Actual) | Interventional | 2015-08-31 | Withdrawn (stopped due to This study was withdrawn prior to enrollment.) |
| Combination Therapy With Sitagliptin (DPP 4 Inhibitor) and Lansoprazole (PPI) Inhibitor) to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes[NCT01155284] | Phase 2 | 70 participants (Actual) | Interventional | 2010-08-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
2 Hour C-peptide AUC in Response to MMTT
Blood samples for C-peptide were collected at baseline (pre-meal) and 15, 30, 60, 90 and 120 minutes post-meal. (NCT01155284)
Timeframe: Month 12
| Intervention | pmol/L (Median) |
|---|
| Sitagliptin and Lansoprazole | 358 |
| Placebo | 495 |
2 Hour C-peptide AUC in Response to MMTT
Blood samples for C-peptide were collected at baseline (pre-meal) and 15, 30, 60, 90, and 120 minutes post-meal. (NCT01155284)
Timeframe: Month 6
| Intervention | pmol/L (Median) |
|---|
| Sitagliptin and Lansoprazole | 485 |
| Placebo | 675 |
Trials
1 trial available for lansoprazole and Diabetes Mellitus, Type 1
| Article | Year |
|---|
Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial.The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Double-Blin | 2014 |
Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial.The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Double-Blin | 2014 |
Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial.The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Double-Blin | 2014 |
Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial.The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Double-Blin | 2014 |
Other Studies
2 other studies available for lansoprazole and Diabetes Mellitus, Type 1
| Article | Year |
|---|
Combination therapy with lansoprazole and cholecalciferol is associated with a slower decline in residual beta-cell function and lower insulin requirements in children with recent onset type 1 diabetes: results of a pilot study.Einstein (Sao Paulo, Brazil), 2022, Volume: 20Topics: Blood Glucose; C-Peptide; Child; Cholecalciferol; Diabetes Mellitus, Type 1; Disease Progression; Hu | 2022 |
Combination therapy with lansoprazole and cholecalciferol is associated with a slower decline in residual beta-cell function and lower insulin requirements in children with recent onset type 1 diabetes: results of a pilot study.Einstein (Sao Paulo, Brazil), 2022, Volume: 20Topics: Blood Glucose; C-Peptide; Child; Cholecalciferol; Diabetes Mellitus, Type 1; Disease Progression; Hu | 2022 |
Combination therapy with lansoprazole and cholecalciferol is associated with a slower decline in residual beta-cell function and lower insulin requirements in children with recent onset type 1 diabetes: results of a pilot study.Einstein (Sao Paulo, Brazil), 2022, Volume: 20Topics: Blood Glucose; C-Peptide; Child; Cholecalciferol; Diabetes Mellitus, Type 1; Disease Progression; Hu | 2022 |
Combination therapy with lansoprazole and cholecalciferol is associated with a slower decline in residual beta-cell function and lower insulin requirements in children with recent onset type 1 diabetes: results of a pilot study.Einstein (Sao Paulo, Brazil), 2022, Volume: 20Topics: Blood Glucose; C-Peptide; Child; Cholecalciferol; Diabetes Mellitus, Type 1; Disease Progression; Hu | 2022 |
Proposal for generating new beta cells in a muted immune environment for type 1 diabetes.Diabetes/metabolism research and reviews, 2013, Volume: 29, Issue:8
Topics: Animals; Cyclosporine; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Ga | 2013 |